ARCHIVES

Q&A With The Cancer Letter: MD Anderson Provost Had No Say

This article is from The Cancer Letter archive.

Vol. 38 No. 21 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

July 26, 2013

ODAC Advice: Avoid ESAs In Curative Settings, Require Patients To Sign Informed Consent.

March 14, 2008

NCI Develops Plan For Specialized Centers, But Funding $67.5M Program Depends On New $$

July 5, 1991

Orphan Designation Granted To Advaxis HPV Immunotherapy

May 30, 2014

NCA To Hear Centers’ Reaction, Other Subcommittee, Scientific Reports

November 11, 1977

Alimta Reduces Risk Of Progression In Patients Aged 70 Years or Older

October 28, 2011